Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
MDRX 
Veradigm Inc. (MDRX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/08/2025: MDRX (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
3 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $5.83
1 Year Target Price $5.83
| 1 | Strong Buy |
| 0 | Buy |
| 2 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -8.76% | Avg. Invested days 45 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/08/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 515.85M USD | Price to earnings Ratio - | 1Y Target Price 5.83 |
Price to earnings Ratio - | 1Y Target Price 5.83 | ||
Volume (30-day avg) 3 | Beta 0.69 | 52 Weeks Range 3.00 - 11.80 | Updated Date 08/8/2025 |
52 Weeks Range 3.00 - 11.80 | Updated Date 08/8/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.18 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-08-08 | When - | Estimate 0.07 | Actual - |
Profitability
Profit Margin -14.7% | Operating Margin (TTM) 16.59% |
Management Effectiveness
Return on Assets (TTM) -0.62% | Return on Equity (TTM) -1.69% |
Valuation
Trailing PE - | Forward PE 15.17 | Enterprise Value 288700000 | Price to Sales(TTM) 0.88 |
Enterprise Value 288700000 | Price to Sales(TTM) 0.88 | ||
Enterprise Value to Revenue 0.49 | Enterprise Value to EBITDA 4.94 | Shares Outstanding 108600000 | Shares Floating 81238736 |
Shares Outstanding 108600000 | Shares Floating 81238736 | ||
Percent Insiders 3.29 | Percent Institutions 41.94 |
Upturn AI SWOT
Veradigm Inc.
Company Overview
History and Background
Veradigm Inc., formerly known as Allscripts Healthcare Solutions, was founded in 1986. It has evolved through acquisitions and strategic partnerships to become a leading provider of healthcare information technology solutions. A significant milestone was the acquisition of Misys Healthcare Systems in 2008. The company rebranded to Veradigm in 2018 to reflect its focus on data-driven insights and connectivity.
Core Business Areas
- Payer Connectivity: Provides solutions for payer enrollment, credentialing, and other administrative tasks.
- Clinical Solutions: Offers electronic health record (EHR) systems, practice management software, and e-prescribing tools for healthcare providers.
- Data and Analytics: Provides healthcare data and analytics solutions to improve clinical decision-making, population health management, and research.
- Research Solutions: Offers access to aggregated patient data for pharmaceutical and biotech companies and research institutions.
Leadership and Structure
The leadership team includes the CEO, CFO, CTO, and other senior executives. The organizational structure is based on functional departments and business units focused on specific product lines and customer segments.
Top Products and Market Share
Key Offerings
- Sunrise EHR: A comprehensive EHR system for hospitals and large healthcare organizations. While specific market share data is difficult to pinpoint, it is a significant player in the enterprise EHR market. Competitors include Epic Systems, Cerner, and Meditech.
- Professional EHR: An EHR solution designed for smaller practices and ambulatory care settings. Competitors include athenahealth, eClinicalWorks, and NextGen Healthcare. Revenue generated from this product line constitutes a substantial portion of Veradigm's clinical segment revenue.
- Veradigm Network: A data and connectivity platform that enables data exchange between payers, providers, and other healthcare stakeholders. Competitors include Change Healthcare (now part of Optum), and Inovalon.
Market Dynamics
Industry Overview
The healthcare IT industry is experiencing growth driven by the increasing adoption of EHRs, the shift towards value-based care, and the growing demand for data analytics and interoperability. Consolidation within the industry is ongoing.
Positioning
Veradigm Inc. is positioned as a leading provider of healthcare IT solutions and data analytics. Its competitive advantages include its extensive network of providers, its comprehensive suite of products, and its expertise in data management and analytics.
Total Addressable Market (TAM)
The total addressable market for healthcare IT is estimated to be in the hundreds of billions of dollars. Veradigm is positioned to capture a portion of this market through its various solutions across provider, payer, and life science segments.
Upturn SWOT Analysis
Strengths
- Established customer base
- Comprehensive product portfolio
- Strong data analytics capabilities
- Extensive network connectivity
Weaknesses
- Debt from prior acquisitions
- Integration challenges from past mergers
- Dependence on regulatory changes
- Complex organizational structure
Opportunities
- Expanding into new markets (e.g., telehealth)
- Developing new data analytics solutions
- Acquiring complementary technologies
- Partnering with other healthcare organizations
Threats
- Increasing competition
- Cybersecurity risks
- Regulatory changes
- Economic downturns
Competitors and Market Share
Key Competitors
- EPIC
- ATHA
- CERN
- DXCM
Competitive Landscape
Veradigm Inc. competes with large, established healthcare IT vendors as well as smaller, niche players. It must differentiate itself through product innovation, customer service, and data analytics capabilities.
Major Acquisitions
Transaction Data Systems (TDS)
- Year: 2017
- Acquisition Price (USD millions): 235
- Strategic Rationale: Expanded Veradigm's pharmacy solutions and enhanced its connectivity to the pharmacy market.
Growth Trajectory and Initiatives
Historical Growth: Veradigm has experienced growth through acquisitions and organic initiatives, but it has also faced challenges related to integration and market competition.
Future Projections: Analyst estimates vary, but generally project moderate revenue growth driven by demand for healthcare IT solutions and data analytics.
Recent Initiatives: Recent initiatives include developing new cloud-based solutions, expanding its data analytics offerings, and partnering with other healthcare organizations.
Summary
Veradigm is a significant player in healthcare IT, offering diverse clinical and data solutions. Its strengths lie in its established network and data analytics. However, debt and competition pose ongoing challenges, requiring strategic initiatives to bolster growth and market position. Successful expansion into new areas, coupled with efficient integration of acquired assets, will be key to sustained success.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Market Research Reports
- Analyst Reports
Disclaimers:
This analysis is based on publicly available information and should not be considered financial advice. Market conditions and company performance are subject to change. Verify all information independently before making investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Veradigm Inc.
Exchange NASDAQ | Headquaters Chicago, IL, United States | ||
IPO Launch date 1999-07-26 | CEO - | ||
Sector Healthcare | Industry Health Information Services | Full time employees 2450 | Website https://veradigm.com |
Full time employees 2450 | Website https://veradigm.com | ||
Veradigm Inc., a healthcare technology company, provides information technology solutions to healthcare providers, payers, and biopharma markets in the United States and internationally. The company offers solutions to healthcare providers, comprising practice management software, AI patient scheduling software, and electronic statements and payments, and payerpath clearinghouse; revenue cycle services and coding services; electronic health records solutions, which include eprescribe with EPCS, EHR software, veradigm EHR, and practice fusion EHR; and patient engagement platform. It also provides solutions to network partners, which comprise API connectivity solutions, such as veradigm connect, veradigm app expo, and diagnostic ordering and resulting network; life sciences, health plans and payers, and providers; and veradigm eprescribe enterprise. In addition, the company offers risk adjustment solutions, such as health equity analytics, risk adjustment analytics, risk mitigator, comprehensive submissions, and utilization analytics; quality analytics, risk adjustment, and quality management; data exchange and coding solutions, including echart courier, echart coder, and echart integration and analytics; clinical data registries for physicians and veradigm payer insights; provider engagement solutions; care gap alerting, gap closure services, and veradigm payerpath solutions. Further, it provides real world data solutions, such as NLP-enriched EHR data solutions, and clinical data registries; real world evidence and real-world evidence analytics platform; and digital health media solutions. The company was formerly known as Allscripts Healthcare Solutions, Inc. and changed its name to Veradigm Inc. in January 2023. Veradigm Inc. was founded in 1986 and is headquartered in Chicago, Illinois.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.